Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029542 · ClinicalTrials.gov registry record
Home Reported Outcomes in C3G Study
A clinical trial of C3 Glomerulopathy, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07029542: Recruiting study of C3 Glomerulopathy, sponsored by Novartis Pharmaceuticals.
NCT07029542 is a study of C3 Glomerulopathy that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 100 participants, below the 113-participant average among 3 other C3 Glomerulopathy trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07029542, a study of C3 Glomerulopathy, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-related Quality of Life (HRQoL) experienced by C3 glomerulopathy (C3G) patients and their caregivers. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treatment usage, supplemented with patient-reported outcome (PRO) measures (collected at baseline and monthly), the study seeks to establish a new real-world data (RWD) source to understand symptom variability and HRQoL as reported by C3G patients and caregivers, including those taking iptacopan
Primary Outcome
Identification of the top 10 symptoms most frequently self-reported by participants, as well as the total number of participants reporting each of those symptoms
Conditions Studied
Study Locations (1)
New Jersey
- Novartis Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2026-04-30 |
What NCT07029542 shows while recruiting
NCT07029542 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 113-participant average among 3 other C3 Glomerulopathy trials with a reported enrollment target (12% lower).
The record links to 1 condition, with C3 Glomerulopathy appearing as the primary indexed condition, and to 0 interventions.
NCT07029542 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT07029542 about?
NCT07029542 is a clinical study titled "Home Reported Outcomes in C3G Study". The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-related Quality of Life (HRQoL) experienced by C3 glomerulopathy (C3G) patients and their caregivers. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treat...
What is the current status of trial NCT07029542?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-04-07. Estimated completion is 2026-04-30.
What conditions does trial NCT07029542 study?
This clinical trial studies the following conditions: C3 Glomerulopathy.
Who is sponsoring clinical trial NCT07029542?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029542 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for C3 Glomerulopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
RECRUITING · Phase 3
-
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
ACTIVE NOT RECRUITING · Phase 3
-
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI